Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central ...

Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital ...

George Tidmarsh, who helmed the FDA’s Center for Drug Evaluation and Research, resigned Sunday following a complaint by biopharma investor Kevin Tang, whose affiliated company, Aurinia Pharmaceuticals ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...

At the center of the licensing deal is an NLRP3 inhibitor that has shown “encouraging efficacy in acute inflammation models,” according to TransThera, indicating its potential in various metabolic and ...

Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...